Ray's Report

   Ray was a healthy consulting design engineer, working 6-7 days per week, and 12 hour days.  He agreed to participate in a study on dmps in Finland in 1991.  He was told by the researchers that dmps was safe, and that there were no serious side effects to the drug.  The researchers did not ask him if he ever had asthma (he had developed stress asthma about a year before the injection) or if he was sulfa-intolerant (he was not, but his mother was).

   Ray became ill almost immediately after the first injection.  He was unable to breathe, suffering serious asthmatic attacks, and experienced severe fatigue lasting for months.  In a period of three months he went from a healthy weight of 200 pounds (he's 6'2" tall), to a ghostly 124 pounds. ("I looked like the ghost of a skeleton.")  His skin turned a jaundiced yellow.

   In the first year following the injection, he was hospitalized in the emergency room due to the DMPS damage to his gastrointestinal tract.  He has developed an acute sensitivity to sulfite... wheezing asthmatic coughing, fatigue, liver/kidney pains, GI gassing and more.  He suffered from severe hypoxia for about three months, during which time long term neurological damage occurred.  He also developed neutropenia.

   He developed autoimmunities which damaged his bones, muscles, organs (liver, kidneys, pancreas), glands (adrenal and thymus), and neural system.  He now has positive antimyelin and ganglioside antibodies, indicating ongoing damage to his nerves.

   He developed both neutropenia and hypercortisolemia... leading to osteoporosis and poor healing.  The dmps caused a severe depletion and dysregulation of essential minerals.  Simple replacement of the depleted minerals has not been successful in restoring them, because the transport enzyme mechanisms were also damaged.

   According to Ray, there were others in the study who also experienced severe side effects. But Ray's reaction, and the reactions of these others, never appeared in the final report.

   Ray is still unable to work full time and has spent thousands of dollars in his attempts to reclaim a semblance of health.  He has spent much of his energy researching dmps, its metabolic effects, and its dangers.  He does not recommend dmps to anyone, but to those who insist on this experimental therapy, he urges a low dose, slow ramp-up protocol.  This protocol minimizes the damage and can alert the patient to side effects and sensitivities early in the process.

   Ray has spent much time and energy lobbying about the dangers of dmps, and has worked hard to educate others.  If you would like to correspond with him about dmps, he can be reached at

Ray’s experience was reported in the medical literature as follows.

McCann. Intravenous gamma globulin (IVIG) treatment of autoimmune kidney disease associated with mercury (Hg++) toxicity. J Allerg Clin Immunol 95(1)(Pt 2):145 Abstract 18 (1995)

ABSTRACT: “Tiny amounts of Hg++ (10(-6)) regularly induce in Brown-Norway rats, but not in outbred strains, autoimmune renal disease characterized by polyclonal activation of B-cells, hypergammaglobulinemia with antibodies against a variety of antigens as well as autoreactive T cells directed against Class II molecules. The same could occur in humans but only in those who are genetically susceptible. RS, a 31 year old Finn, developed fatigue and recurrent infections (aseptic meningitis, pneumonia, sinusitis, pseudomonas pyelonephritis) beginning at age 9. He was heavily exposed to Hg++. Urine Hg=>800ug/L. His illness exacerbated following simultaneous removal of 21 large Hg-amalgam fillings along with chelation therapy (EDTA & DMPS). Over the next year he had 70lb weight loss, gastroenteritis, monilial stomatitis, granulocytopenia, and proteinuria. IgG-14.6gm/L, CD8 lymphocytes=50% CD4/CD8=0.9, CD8 HLADR=20u/L(N=>149). Antimyelin IgM antibody was positive. The only successful treatment was IVIG, 400mg/ Creatinine Cl,60ml/min increased to >, proteinuria cleared and weight gain resumed. His illness resembled AIDS but repeated HIV testing was negative. This case suggests that traditional toxicological thinking in which symptoms should be dose related to total body Hg++ burden in all individuals in a group, needs to be changed to recognize genetic variability.”

Last Updated: Friday, May 11, 2001 11:20 PM is optimized for Microsoft Internet Explorer in 800x600 resolution Please read our privacy, terms, and conditions agreement
Site Design By: Ryan H. Smith